January 27, 2022Annual Review of Medicine
Hypertrophic Cardiomyopathy: New Concepts and Therapies
Key result
Modern HCM management reduces disease-related mortality to 0.5% per year.
Population
Patients with Hypertrophic cardiomyopathy (HCM)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports contemporary HCM management in practice; leaves open optimal implementation and equity in diverse populations.
Structured PICO
P
Population
Patients with Hypertrophic cardiomyopathy (HCM)
I
Intervention
Modern management strategies including prophylactic implantable defibrillators, surgical myectomy, anticoagulation prophylaxis, and heart transplant
O
Outcome
HCM-related morbidity and mortality
Modern management strategies, including ICDs, myectomy, and anticoagulation, have transformed HCM into a treatable condition with a low annual mortality rate of 0.5%.
Cite This Study
Maron et al. (2022) conducted a review in Hypertrophic cardiomyopathy. Modern management strategies (ICDs, surgical myectomy, anticoagulation, heart transplant) was evaluated on HCM-related mortality. Modern management strategies for hypertrophic cardiomyopathy, including ICDs, surgical myectomy, anticoagulation, and heart transplant, have reduced disease-related mortality to 0.5% per year.